Revolution Medicines target raised to $241 from $240 by Truist Securities
RVMD•Truist Securities raised its price target for Revolution Medicines to $241 from $240.
Related News
Knox and Palantir partner to accelerate software delivery through largest federal cloud
PLTR•
Gold edges up as oil retreat lends support; Fed decision in focus
GLD•
Strive buys 4,045 bitcoin, lifting holdings to 36,818
ASST•
Fifth Third Bancorp outlook: Q4 NII up 2.5%-3.5%
FITB•
Cytokinetics wins Health Canada approval for MYQORZO to treat obstructive HCM
CYTK•